Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 13,075 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Retinoblastoma, Retinoblastoma Bilateral, Retinoblastoma Unilateral
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 0 Years to 18 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 5 more

Conditions: HIV, HIV Infections
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Retroperitoneal Liposarcoma
Interventions: Not listed
Lead sponsor: Australia and New Zealand Sarcoma Association; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Columbus, Ohio + 1 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more

Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions: OP-1250; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
Interventions: Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 37 Months to 21 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: Ropivacaine 0.5%, Percocet 7.5/325, Naprosyn 500 mg; Drug
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 80
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more

Conditions: Alcohol Use Disorder, Hiv, Tobacco Use Disorder
Interventions: Varenicline; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Cutaneous T-cell Lymphoma (CTCL),
Interventions: Forodesine 200 mg; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 16 more

Conditions: Retinitis Pigmentosa
Interventions: Spin exercise; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Macular Edema
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more

Conditions: Pelvic Pain Associated With Refractory Endometriosis
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions: RVU120(SEL120); Drug
Lead sponsor: Ryvu Therapeutics SA; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine; Biological · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 30
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more

Conditions: Heart Failure
Interventions: Glial growth factor 2/ Neuregulin 1β3, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia • Nashville, Tennessee

Conditions: Acute Stroke, Ischemic Stroke, Stroke
Interventions: Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection; Drug · Other
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more

Conditions: Low Back Pain
Interventions: Vertis Percutaneous Neuromodulation Therapy (PNT), Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: RS Medical; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: La Jolla, California • Atlanta, Georgia • Eugene, Oregon + 5 more

Conditions: Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions: Lenvatinib; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Prednisone or methylprednisolone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 29 more

Conditions: Carotid Artery Disease
Interventions: Not listed
Lead sponsor: Silk Road Medical; Industry
Eligibility: 18 Years and older
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 41
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 34 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Metformin, Insulin, Placebo, Linagliptin, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more

Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions: Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 29 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 163
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more

Search by objective public record fields.

Retinoblastoma Patient Clinical Database and Tissue Repository

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Anterior Cruciate Ligament Pain Study

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Exercise and RP (AVAMC and Emory)

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma